Abner Antonio Murray/Bluesky
Jun 5, 2025, 09:02
Abner Antonio Murray: EQUAL Study Redefines Lung Cancer Screening for Nonsmokers
Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared a post by FlorezLab, adding:
“The EQUAL study presented at ASCO25 by FlorezLab is redefining who gets screened for lung cancer. Using blood-based EGFR ctDNA testing in Latinx and East/Southeast Asian nonsmokers, this trial is paving a path toward equity in early detection.
Over 60% of EGFR+ lung cancers occur in people not eligible for current screening guidelines
EQUAL reaches those excluded — never/light smokers, community settings, multiple languages
Plasma EGFR ctDNA detection with mobile phlebotomy = feasible, accessible, scalable
Real-world implementation underway across DFCI, MGH, BIDMC and moreA bold, community-rooted approach to dismantle disparities in LCSM.”
Quoting FlorezLab‘s post:
“Thank you to everyone that came to visit our EQUAL study poster ASCO. We are so happy to have had the opportunity to present this amazing study and are grateful for the love and support from everyone for EQUAL.”
More posts featuring Abner Antonio Murray.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 19, 2025, 11:05
Jul 19, 2025, 10:29
Jul 19, 2025, 10:12
Jul 19, 2025, 09:55
Jul 19, 2025, 09:05
Jul 19, 2025, 08:54
Jul 19, 2025, 07:24
Jul 19, 2025, 07:23